Yesterday, Bloomberg's restless team of deal-watchers proffered Bristol-Myers Squibb ($BMY) as a possibility, seeing as how the Big Biotech is now the clear leader in immuno-oncology, where it could be in line for $15 billion in peak sales. Today WINDSOR, ON / ACCESSWIRE / March 9, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce some recent breakthroughs in the The short interest data are out for the February 27 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. The big hospital system’s Clinical Biotechnology Research Institute in downtown Charleston is unveiling its second act, what it calls “the innovation arm.” It has lined up nearly $400,000 from donors to fund the effort, which it expects to become There's nothing better than getting a great value -- and let's face it, when the market tumbles, often great stocks get crushed too. That could end up being particularly true in biotech. Since 2013, the industry's return has tripled the S&P 500's return Unlike conventional agriculture, agri-biotechnology has positive effect on the environment, including helping mitigate climate change. Such is one of the findings of a study dubbed the “Global Status of Commercialized Biotech/GM Crops in 2014.” .
The big news last week was AbbVie’s (ABBV - Analyst Report) decision to acquire Pharmacyclics (PCYC - Analyst Report). Moreover, the biotech sector will be facing some new challenges with the FDA approving the first biosimilar in the U.S. – Sandoz’s WINSTON-SALEM, N.C. — The pending sale of Targacept Inc. – Winston-Salem’s biotechnology face for nearly 15 years – signifies both the ending of a high-profile era and a fresh example of the volatility that comes with hitching economic fortunes to Back in early April 2012, in a special report for Private Briefing readers called "The Biotech Buyout Binge," I explained that we would start seeing a slew of takeovers - engineered by cash-rich biopharmaceutical firms desperate to replace blockbusters The global biotechnology industry is well established and rebounded strongly in the recent time. The Indian biotechnology sector has emerging market characteristics and is one of the fastest growing knowledge- based sectors, and is expected to play a key r .
- biotechnology in Pluripotent stem cells generated from human urine cells used to grow 166 x 138 · 5 kB · jpeg
- biotechnology in progress in AI, from developments in biotechnology and artificial life 140 x 104 · 7 kB · jpeg
- biotechnology in Biosciences Presents Positive Preclinical Data on HCV Product 186 x 186 · 7 kB · jpeg
- biotechnology in Oligonucleotide and Peptide Research, Technology & Product Development 160 x 120 · 5 kB · jpeg
- biotechnology in Baby Quasar 140 x 140 · 9 kB · jpeg
- biotechnology in qPCR & Digital PCR Congress 149 x 112 · 4 kB · jpeg
- biotechnology in Cellular Variation Paul Andersen explains how variation is created 120 x 90 · 6 kB · jpeg
- biotechnology in From Biotech Nutrition, Moore Mall, Ilac Centre - Proteins - ISO Whey 150 x 150 · 8 kB · jpeg
- biotechnology in EMBL Advanced Course: Whole Transcriptome Data Analysis 160 x 160 · 7 kB · jpeg
- biotechnology in BCM Researchers Discover That A Little Less Protein May Be Answer In 150 x 188 · 8 kB · jpeg
biotechnology in Image Gallery
No comments:
Post a Comment